Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia

By Chu Yu-Waye   Polson Andrew  

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 355-368

Future Medicine

Access to resources Recommend Favorite

Iodine 131 tositumomab in the treatment of non-Hodgkin’’s lymphoma

By Smith Stephen   Sweetenham John W  

Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. : 255-262

Future Medicine

Access to resources Recommend Favorite

Erratum to: Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma

By Morales La Madrid Andres   Campbell Nicholas   Smith Sonali   Cohn Susan   Salgia Ravi  

Targeted Oncology, Vol. 8, Iss. 4, 2013-12 ,pp. : 301-301

Springer Publishing Company

Access to resources Recommend Favorite

CD20-specific antibody-targeted chemotherapy of non-Hodgkin’s B-cell lymphoma using calicheamicin-conjugated rituximab

By DiJoseph John   Dougher Maureen   Armellino Douglas   Kalyandrug Lyka   Kunz Arthur   Boghaert Erwin   Hamann Philip   Damle Nitin  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 7, 2007-07 ,pp. : 1107-1117

Springer Publishing Company

Access to resources Recommend Favorite

Anthracyline-reduced sequential combination chemotherapy for younger patients with good-prognosis aggressive B-cell non-Hodgkin’s lymphoma

By Schütt P.   Zimmermann K.   Derks C.   Ebeling P.   Welt A.   Poser M.   Hense J.   Metz K.   Anhuf J.   Sandmann M.   Neise M.   Moritz T.   Stuschke M.   Niederle N.   Seeber S.   Nowrousian Mohammad  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 459-466

Springer Publishing Company

Access to resources Recommend Favorite